

Edgar Filing: Aimmune Therapeutics, Inc. - Form 8-K

Registrant's telephone number, including area code: (650) 614-5220

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On November 11, 2015, Aimmune Therapeutics, Inc. (“Aimmune” or the “Company”) issued a press release reporting positive findings for its ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy. The Company also announced that it intends to release full ARC002 data at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in March 2016. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Reference is made to the Exhibit Index attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AIMMUNE THERAPEUTICS, INC.

Date: November 11, 2015 By: /s/ Warren L. DeSouza

Warren L. DeSouza

Chief Financial Officer and Corporate Secretary

EXHIBIT INDEX

Exhibit

Number Description

99.1 Press release dated November 11, 2015.